A Comparison of the Effects of an Experimental Immunotherapy for Melanoma in Combination with a Drug called Ipilimumab (Yervoy™) vs. Ipilimumab (Yervoy™) alone

What we are studying

The purpose of this study is to examine the effectiveness (how well the drug works) of a drug called ipilimumab (Yervoy™) either given alone or in combination with an experimental immunotherapy drug for melanoma. We want to see if the combination is better than the ipilimumab given by itself. Ipilimumab at a dose of 3 mg/kg has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic melanoma.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Stage IV Melanoma
  • No prior treatment with CTLA4 antibodies
  • ?4 weeks since last treatment or surgery

What is involved

  • Normal exams
  • Normal imaging
  • Ipilimumab treatment
  • Blood Collection
  • Tumor and Skin Biopsies
  • Study drug injections (if randomized to study drug)

Contact Information

Study Coordinator
Joyce Fenstermaker
Email
jfenster@wakehealth.edu
Phone
336-713-3155

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.